<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: There is evidence that acutely elevated blood pressure (BP) after <z:hpo ids='HP_0001297'>stroke</z:hpo> is associated with increased <z:hpo ids='HP_0001342'>cerebral hemorrhage</z:hpo> and <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Previous experiments in our laboratory have shown that <z:chebi fb="0" ids="3347">candesartan</z:chebi> 1 mg/kg administered after reperfusion in a model of <z:hpo ids='HP_0000822'>hypertension</z:hpo> after experimental <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> reduces neurovascular damage and improves outcome </plain></SENT>
<SENT sid="2" pm="."><plain>These results could be either mediated by BP lowering or a BP-independent cerebrovascular protective effect </plain></SENT>
<SENT sid="3" pm="."><plain>OBJECTIVES: To determine the contribution of BP lowering to the neurovascular protection previously reported with <z:chebi fb="0" ids="3347">candesartan</z:chebi> after <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Male Wistar rats (280-305 g) underwent 3 h of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="5" pm="."><plain>At reperfusion, either hydralazine 1 mg/kg (n = 8), enalapril 5 mg/kg (n = 7) or enalapril 10 mg/kg (n = 8) were administered intravenously </plain></SENT>
<SENT sid="6" pm="."><plain>BP was measured by telemetry for 2 days before and 24 h after MCAO </plain></SENT>
<SENT sid="7" pm="."><plain>After neurological function was assessed, brain tissue was processed for <z:mpath ids='MPATH_124'>infarct</z:mpath> size and <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> content analyses </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: Mean arterial pressure (MAP) increased from 92 to 124 mmHg immediately upon MCAO and decreased to 112 mmHg after reperfusion, remaining elevated for 24 h (P &lt; 0.0001) in the saline group </plain></SENT>
<SENT sid="9" pm="."><plain>Hydralazine <z:mp ids='MP_0004876'>reduced MAP</z:mp> (P = 0.048) and <z:mpath ids='MPATH_124'>infarct</z:mpath> size (53 versus 30%, P = 0.0083), and there was a trend towards <z:mp ids='MP_0002874'>decreased hemoglobin content</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Enalapril 5 mg/kg did not significantly change MAP or other outcomes </plain></SENT>
<SENT sid="11" pm="."><plain>Enalapril 10 mg/kg <z:mp ids='MP_0004876'>reduced MAP</z:mp> (P &lt; 0.0001) and <z:mpath ids='MPATH_124'>infarct</z:mpath> size (53 versus 29%, P = 0.003) </plain></SENT>
<SENT sid="12" pm="."><plain>There was an intermediate effect on both <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> content and neurological function, neither one was significant </plain></SENT>
<SENT sid="13" pm="."><plain>The time course of BP lowering varied with each treatment </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: <z:hpo ids='HP_0011009'>Acute</z:hpo> BP lowering after reperfusion in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> is an effective strategy to achieve neurovascular protection </plain></SENT>
<SENT sid="15" pm="."><plain>The rate, extent and mechanism of BP lowering may determine the magnitude of protection </plain></SENT>
</text></document>